Neurocrine Biosciences released new survey findings during Tardive Dyskinesia Awareness Week showing that tardive dyskinesia significantly affects employment, productivity, and daily functioning, while highlighting ongoing gaps in diagnosis and treatment.
Written By: Dr. Preethi Putti, PharmD
Reviewed By: Dr. Aabhijeet Ghangale,
MBBS, MS, M.Ch in Neurosurgery
Neurocrine Biosciences has announced new survey results highlighting the significant burden that tardive dyskinesia (TD) places on employment and daily functioning. The findings were released during Tardive Dyskinesia Awareness Week to emphasize the importance of increased awareness, early recognition, and appropriate management of TD.
The online quantitative survey was conducted in the United States by Ipsos on behalf of Neurocrine Biosciences between January 15 and February 17, 2026. The survey included 100 participants, including 70 adults diagnosed with TD by a healthcare professional and 30 caregivers of individuals living with TD. The findings are based on self-reported responses and reflect real-world patient and caregiver experiences rather than controlled clinical outcomes.
Understanding Tardive Dyskinesia
Tardive dyskinesia is a persistent movement disorder characterized by involuntary, repetitive movements that can affect the face, tongue, jaw, torso, and extremities. TD is commonly associated with prolonged exposure to dopamine receptor-blocking agents, including certain antipsychotic medications used to treat mental health conditions.
These involuntary movements can interfere with communication, concentration, coordination, and other physical functions that are essential in daily activities and workplace environments. TD can persist for years and may not resolve without appropriate clinical management, making early recognition and treatment particularly important.
It is estimated that TD affects at least 800,000 adults in the United States, although experts believe many cases remain undiagnosed or untreated.
Survey Reveals Workplace Impact
Among 59 adults with TD who reported being employed, attending school, volunteering, or actively seeking employment, approximately one in five respondents said they had quit a job primarily because of TD symptoms. In addition, 19 respondents reported stepping down from work-related responsibilities or changing job duties due to the condition.
All 59 respondents also reported missing an average of eight hours of work or school during the week before starting TD treatment, highlighting the substantial impact the disorder may have on productivity and participation in daily life when left untreated.
Although limited by a relatively small sample size, the survey provides insight into the occupational and functional challenges experienced by individuals living with TD.
Daily Challenges Extend Beyond Movement Symptoms
Beyond physical symptoms, TD may also affect emotional well-being, confidence, and social interaction. Involuntary movements can make communication difficult and may contribute to embarrassment, anxiety, social withdrawal, and challenges in maintaining professional responsibilities.
The survey findings reinforce that TD is not only a neurological condition but also a disorder that can significantly affect independence, identity, and quality of life for patients and caregivers alike.
Treatment Gap Continues Despite Available Therapies
Many survey participants reported perceived improvements in their ability to work and manage daily activities after receiving treatment or supportive care. Clinical guidance from the American Psychiatric Association recommends treatment with a VMAT2 inhibitor for individuals with moderate-to-severe TD, or for patients with milder symptoms that disrupt functioning.
FDA-approved VMAT2 inhibitors for TD include INGREZZA and Austedo.
Despite the availability of approved therapies, previous estimates suggest that only about 10% of eligible individuals with TD receive treatment with a VMAT2 inhibitor. Neurocrine Biosciences markets INGREZZA in the United States for the treatment of tardive dyskinesia.
Importance of Early Recognition and Screening
Advocates and healthcare experts continue to stress the importance of education and early detection, as many individuals may not recognize that involuntary movements are symptoms of TD. Routine screening, symptom monitoring, and open communication between patients and healthcare providers may help improve diagnosis and treatment rates.
Josie Cooper, Executive Director of the Movement Disorders Policy Coalition, stated that many individuals may not realize their involuntary movements are signs of tardive dyskinesia, despite the condition affecting important aspects of daily life, including work, education, and social identity.
Neurocrine Biosciences said its TD awareness resources are designed to help patients, caregivers, and healthcare professionals better understand the condition, recognize symptoms earlier, and explore available treatment options. The company also encourages proactive management approaches, including regular assessments and discussions between patients and healthcare providers.
TD Awareness Week Highlights Unmet Needs
TD Awareness Week brings together the mental health and movement disorder communities to recognize the physical, emotional, and social burden associated with tardive dyskinesia. The initiative also aims to encourage earlier evaluation by healthcare professionals and improve awareness of available FDA-approved treatment options.
By highlighting the real-world experiences of individuals living with TD, Neurocrine Biosciences said the survey underscores the need for greater public understanding, earlier intervention, and improved access to care for people affected by the disorder.
References
About the Writer
Dr.Preethi Putti, PharmD is a pharmaceutical researcher with experience in healthcare and pharmaceutical market research and competitive intelligence. She specializes in analyzing drug pipelines, clinical data, and industry trends and translating complex scientific data into clear and structured medical content. Strong foundation in clinical research, data interpretation, and evidence-based healthcare analysis. Committed to advancing a global career in clinical research and healthcare innovation.